CASI Pharmaceuticals, Inc. (PNK: CASIF) Stock Competitors & Peer Comparison

CASI Pharmaceuticals, Inc. (PNK: CASIF) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CASIF stands at 2.6M. In comparison, SGMO has a market cap of 30.7M. Regarding current trading prices, CASIF is priced at $0.13 on the PNK, while SGMO trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CASIF currently has a P/E ratio of -0.05, whereas SGMO's P/E ratio is -0.20. In terms of profitability, CASIF's ROE is +2.04%, compared to SGMO's ROE of +66.86%. Regarding short-term risk, CASIF is less volatile compared to SGMO. This indicates lower risk in terms of short-term price fluctuations for CASIF.Check SGMO's competition here

CASI Pharmaceuticals, Inc. (PNK: CASIF) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CASIF stands at 2.6M. In comparison, ADTX has a market cap of 3.7M. Regarding current trading prices, CASIF is priced at $0.13 on the PNK, while ADTX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CASIF currently has a P/E ratio of -0.05, whereas ADTX's P/E ratio is N/A. In terms of profitability, CASIF's ROE is +2.04%, compared to ADTX's ROE of +9.26%. Regarding short-term risk, CASIF is less volatile compared to ADTX. This indicates lower risk in terms of short-term price fluctuations for CASIF.Check ADTX's competition here

CASI Pharmaceuticals, Inc. (PNK: CASIF) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CASIF stands at 2.6M. In comparison, ITRMF has a market cap of 2.7M. Regarding current trading prices, CASIF is priced at $0.13 on the PNK, while ITRMF trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CASIF currently has a P/E ratio of -0.05, whereas ITRMF's P/E ratio is -0.07. In terms of profitability, CASIF's ROE is +2.04%, compared to ITRMF's ROE of +4.42%. Regarding short-term risk, CASIF is less volatile compared to ITRMF. This indicates lower risk in terms of short-term price fluctuations for CASIF.Check ITRMF's competition here

CASI Pharmaceuticals, Inc. (PNK: CASIF) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CASIF stands at 2.6M. In comparison, OCEA has a market cap of 237.3K. Regarding current trading prices, CASIF is priced at $0.13 on the PNK, while OCEA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CASIF currently has a P/E ratio of -0.05, whereas OCEA's P/E ratio is N/A. In terms of profitability, CASIF's ROE is +2.04%, compared to OCEA's ROE of +0.04%. Regarding short-term risk, CASIF is less volatile compared to OCEA. This indicates lower risk in terms of short-term price fluctuations for CASIF.Check OCEA's competition here

CASI Pharmaceuticals, Inc. (PNK: CASIF) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CASIF stands at 2.6M. In comparison, AFMDQ has a market cap of 1.6K. Regarding current trading prices, CASIF is priced at $0.13 on the PNK, while AFMDQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CASIF currently has a P/E ratio of -0.05, whereas AFMDQ's P/E ratio is N/A. In terms of profitability, CASIF's ROE is +2.04%, compared to AFMDQ's ROE of -1.01%. Regarding short-term risk, CASIF is similarly volatile compared to AFMDQ. This indicates similar risk in terms of short-term price fluctuations for CASIF.Check AFMDQ's competition here

CASI Pharmaceuticals, Inc. (PNK: CASIF) plays a significant role within the Healthcare sector. Its performance on the PNK reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CASIF stands at 2.6M. In comparison, BIORQ has a market cap of 905. Regarding current trading prices, CASIF is priced at $0.13 on the PNK, while BIORQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CASIF currently has a P/E ratio of -0.05, whereas BIORQ's P/E ratio is N/A. In terms of profitability, CASIF's ROE is +2.04%, compared to BIORQ's ROE of +1.22%. Regarding short-term risk, CASIF is similarly volatile compared to BIORQ. This indicates similar risk in terms of short-term price fluctuations for CASIF.Check BIORQ's competition here